Resolving inflammatory organ disease through macrophage cell therapy

Inflammatory organ disease affects millions of patients worldwide. We aim to treat these patients, for example by helping patients with liver cirrhosis avoiding the need for a transplantation.

The Science +

Harnessing the healing power of the macrophage

Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, manufacture and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.

Latest News

30/06/2022

Resolution Therapeutics Appoints Dr Amol Ketkar as Chief Development Officer

London, 30 June, 2022 – Resolution Therapeutics announces the appointment of Dr. Amol Ketkar, as Chief Development Officer.

READ MORE +
05/04/2022

Resolution Therapeutics and panCELLa Inc announce a Research Evaluation and Option Agreement to develop iPSC-derived macrophage cell therapy for inflammatory organ disease

London and Toronto, 5 April 2022 - Resolution Therapeutics partners with panCELLa to develop iPSC-derived macrophage cell therapy for inflammatory organ disease.

READ MORE +
05/04/2022

Resolution Therapeutics Announces a £10m Extended Series A Financing from Syncona Ltd

London, 5 April 2022 - Resolution Therapeutics announces a £10M Series A extension to broaden its research pipeline into allogeneic macrophages for the treatment of liver disease.

READ MORE +
17/02/2022

Resolution Therapeutics Strengthens its Team with Two New Appointments

London, 17 February 2022 – Resolution Therapeutics announces the strengthening of its senior management team with the appointments of Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance.

READ MORE +
12/04/2021

Resolution Therapeutics Appoints Lisa Bright to its Board of Directors

London, 12 April 2021 – Resolution Therapeutics announces the appointment of Lisa Bright as a Non-Executive Director of the Company.

READ MORE +

Chairman's Statement

Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.

Edward Hodgkin Chairman & CEO